Quarterly report pursuant to Section 13 or 15(d)

5. Hybrid Debt Instrument (Details Narrative)

v3.5.0.2
5. Hybrid Debt Instrument (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Loss on conversion $ 0 $ 0 $ (6,187,337) $ 0
Interest expense     341,000 690,000
Loss on issuance of debt hybrid (106,566) $ 0 $ (1,690,787) $ (59,612)
Hybrid Debt Instrument [Member] | Pharmsynthez [Member]        
Stock issued for convertible note, shares issued     1,373,036  
Stock issued for convertible note, amount converted     $ 6,500,000  
Accrued interest converted     228,000  
Loss on conversion     (4,400,000)  
Convertible Note [Member] | M. Scott Maguire [Member]        
Convertible note face value 369,958   $ 369,958  
Warrants issued     37,369  
Debt maturity date     Sep. 30, 2016  
Further Note 1 [Member]        
Convertible note face value 178,000   $ 178,000  
Further Note 2 [Member]        
Convertible note face value $ 322,000   $ 322,000  
Further Notes [Member]        
Warrants issued 50,505      
Loss on issuance of debt hybrid $ (106,566)